NDAORALCAPSULEPriority Review
Approved
Jan 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
CHEMET (succimer) by Recordati is lead chelating activity [moa]. Approved for lead poisoning in pediatric patients aged 1 year, older with blood lead levels above 45 mcg/dl, lead poisoning in a lead-containing environment and 1 more indications. First approved in 1991.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHEMET (succimer) is an oral lead chelator approved in 1991 for treating lead poisoning in pediatric patients aged 1 year and older with blood lead levels above 45 mcg/dL. It works by binding lead in the bloodstream and facilitating urinary excretion, preventing neurotoxic damage. The drug is indicated for acute lead poisoning and lead encephalopathy in children exposed to lead-containing environments.
$0.153MPart D
LOE ApproachingMinimal commercial momentum with only $153K Part D spending and 55 claims in 2023; expect downsized team as LOE approaches and generic competition increases.
Mechanism of Action
Lead Chelating Activity
Pharmacologic Class:
Lead Chelator
Worked on CHEMET at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.